Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016

S. L. Grupke, J. F. Fraser

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.

Original languageEnglish
Title of host publicationDrug Discovery for Leishmaniasis
EditorsSvetlana A. Dambinova, Thomas A. Gennarelli, Philip V. Peplow, Thomas A. Gennarelli, Bridget Martinez
Pages242-262
Number of pages21
Edition62
DOIs
StatePublished - 2018

Publication series

NameRSC Drug Discovery Series
Number62
Volume2018-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Bibliographical note

Funding Information:
Drug Discovery Series No. 62 Acute Brain Impairment: Scientific Discoveries and Translational Research Edited by Philip V. Peplow, Svetlana A. Dambinova, Thomas A. Gennarelli and Bridget Martinez © The Royal Society of Chemistry 2018 Published by the Royal Society of Chemistry, www.rsc.org

Publisher Copyright:
© The Royal Society of Chemistry 2018.

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016'. Together they form a unique fingerprint.

Cite this